1. Academic Validation
  2. Discovery and validation of anti-arthritic ingredients and mechanisms of Qingfu Juanbi Tang, a Chinese herbal formulation, on rheumatoid arthritis

Discovery and validation of anti-arthritic ingredients and mechanisms of Qingfu Juanbi Tang, a Chinese herbal formulation, on rheumatoid arthritis

  • J Ethnopharmacol. 2024 Mar 31:329:118140. doi: 10.1016/j.jep.2024.118140.
Muzi Peng 1 Zhongliu Yao 2 Junlan Zhang 3 Ye Lin 3 Li Xu 3 Qin Zhang 4 Jing Liao 5 Xiong Cai 6
Affiliations

Affiliations

  • 1 Department of Rheumatology of First Hospital, Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China; Institute of Innovation and Applied Research in Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China.
  • 2 Department of Rheumatology of First Hospital, Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China.
  • 3 Institute of Innovation and Applied Research in Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China.
  • 4 Department of Rheumatology of First Hospital, Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China. Electronic address: dboyzq1@163.com.
  • 5 Institute of Innovation and Applied Research in Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China. Electronic address: liaojing@hnucm.edu.cn.
  • 6 Department of Rheumatology of First Hospital, Hunan University of Chinese Medicine, Changsha, Hunan, 410007, China; Institute of Innovation and Applied Research in Chinese Medicine, Hunan University of Chinese Medicine, Changsha, Hunan, 410208, China. Electronic address: caixiong@hnucm.edu.cn.
Abstract

Ethnopharmacological relevance: Qingfu Juanbi Tang (QFJBT), a novel and improved Chinese herbal formulation, has surged in recent years for its potential in the therapy of rheumatoid arthritis (RA). Anti-arthritic effects and underlying molecular mechanisms of QFJBT have increasingly become a focal point in research.

Aim of the study: This study utilized network pharmacology, molecular docking, and experimental validation to elucidate effective ingredients and anti-arthritic mechanisms of QFJBT.

Materials and methods: Targets associated with QFJBT and RA were identified from relevant databases and standardized using the Uniprot for gene nomenclature. A "QFJBT-ingredient-target network" and a "Venn diagram of QFJBT and RA targets" were created from the data. The overlap in the Venn diagram highlighted potential targets of QFJBT in the treatment of RA. These targets were subjected to PPI network, GO, and KEGG pathway analysis. The findings were subsequently confirmed through molecular docking and pharmacological experiments to propose the mechanism of action of QFJBT.

Results: The study identified 236 active ingredients in QFJBT, with 120 predicted to be effective against RA. Molecular docking showed high binding affinity of key targets (JUN, PTGS2, and TNF-α) with bioactive compounds (rhein, sinomenine, calycosin, and paeoniflorin) of QFJBT. Pharmacodynamic evaluation demonstrated the effects of QFJBT at the dose of 4.56 g/kg in ameliorating symptoms of AIA rats and in reducing levels of JUN, PTGS2, and TNF-α in synovial tissues. In vitro studies further exhibited that rhein, paeoniflorin, sinomenine, calycosin, and QFJBT-containing serum significantly inhibited abnormal proliferation of RA fibroblast-like synoviocytes. Interestingly, rhein and paeoniflorin specifically decreased p-JUN/JUN expression and TNF-α release, respectively, while sinomenine and calycosin selectively increased PTGS2 expression. Consistently, QFJBT-containing serum demonstrated similar effects as those active ingredients identified in QFJBT did.

Conclusions: QFJBT, QFJBT-containing serum, and its active ingredients (rhein, paeoniflorin, sinomenine, and calycosin) suppress inflammatory responses in RA. Anti-arthritic effects of QFJBT and its active ingredients are likely linked to their modulatory impact on identified hub targets.

Keywords

Molecular docking; Molecular mechanisms; Network pharmacology; Qingfu Juanbi Tang; Rheumatoid arthritis.

Figures
Products